How would you approach an older cardiac patient with borderline resectable pancreatic adenoca (BRCA2+) with squamous differentiation progressing on neoadjuvant gem abraxane?
Would you favor a platinum radiosensitizer? Is there a role for PARP inhibitors in the neo-adjuvant setting?